Last reviewed · How we verify
(+/-)-Theodrenaline (THEODRENALINE)
(+/-)-Theodrenaline (generic name: THEODRENALINE) is a theodrenaline drug. It is currently in Phase 2 development.
Theodrenaline is believed to work by interacting with the body's adrenergic system.
Theodrenaline, also known as noradrenaline theophylline, is a small molecule. It has multiple synonyms, including TEODRENALINA, THEODRENALINE, and THEODRENALINE.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | THEODRENALINE |
|---|---|
| Drug class | theodrenaline |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's adrenergic system as a messenger network that helps you respond to stress and excitement. Theodrenaline is thought to send signals through this network to help your body react to certain situations. This can lead to increased heart rate, blood pressure, and energy levels, but more research is needed to fully understand its effects.
Approved indications
Common side effects
Key clinical trials
- Cafedrin/Theodrenalin (Akrinor®) Versus Ephedrine for Treatment of Hypotension in the Peri-operative Phase in Inpatient Setting
- Non-invasive Early Goal Directed Therapy in Colorectal Surgery: a Feasibility Study (NA)
- Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- (+/-)-Theodrenaline CI brief — competitive landscape report
- (+/-)-Theodrenaline updates RSS · CI watch RSS
Frequently asked questions about (+/-)-Theodrenaline
What is (+/-)-Theodrenaline?
How does (+/-)-Theodrenaline work?
What is the generic name of (+/-)-Theodrenaline?
What drug class is (+/-)-Theodrenaline in?
What development phase is (+/-)-Theodrenaline in?
Related
- Drug class: All theodrenaline drugs
- Therapeutic area: All drugs in Nephrology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing